Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.
Actively Recruiting
Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.